NCT03867747

Brief Summary

Patients with refractory ventricular extrasystoles or tachycardia not eligible for catheter ablation will receive single fraction stereotactic body radiation therapy (cardiac radiosurgery) with 25 Gy. Investigators initiated this study to demonstrate that in at least 70% of the patients the planned cardiac radiosurgery may be performed without any interruption or treatment related interventional events within the first 30 days after treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 5, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 8, 2019

Completed
9 months until next milestone

Study Start

First participant enrolled

December 2, 2019

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2023

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 20, 2024

Completed
Last Updated

January 8, 2025

Status Verified

January 1, 2025

Enrollment Period

4 years

First QC Date

March 5, 2019

Last Update Submit

January 6, 2025

Conditions

Keywords

Ventricular TachycardiaStereotactic Body Radiation TherapyRadiosurgery

Outcome Measures

Primary Outcomes (1)

  • Acute toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports

    30 days after radiosurgery

Secondary Outcomes (4)

  • Late toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports

    12 months after radiosurgery

  • Ventricular tachycardia burden reduction analysed by number of episodes and ICD shocks

    At the time of inclusion and 12 months after radiosurgery

  • Overall Survival

    12 months after radiosurgery

  • Quality of Life questionnaire

    At the time of inclusion and 12 months after radiosurgery

Study Arms (1)

Cardiac Radiosurgery

EXPERIMENTAL

25 Gy in a single fraction

Radiation: Cardiac Radiosurgery

Interventions

Image-guided stereotactic body radiation therapy

Cardiac Radiosurgery

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with structural heart disease and implantable cardioverter defibrillator (ICD)
  • Age \> 18 years
  • either
  • induction of symptomatic monomorphic ventricular tachycardia that requires ICD intervention (e.g. shock or anti-tachycardia stimulation). Induction triggered by ICD or during electrophysiology studies (EPS) or both, a) and b)
  • Refractory to antiarrhythmic combination therapy
  • Beside the cardiac conditions: No competing illness that would additionally limit the life expectancy to less than 6 months
  • No prior radiation therapy in the thorax area
  • No pregnancy and no active breastfeeding
  • Ability to consent and consent to study participation

You may not qualify if:

  • ICD electrode malfunction of ICD readings outside reference range
  • Lack of evidence of a myocardial scar (Computer tomography or magnetic resonance tomography for MRI-capable ICD aggregates or electrophysiological measurement)
  • No possible induction of symptomatic monomorphic ventricular tachycardia non-persistent or persistent with delivery of ICD therapies such as antitachycardic pacing or shock
  • Contraindication to radiosurgery (e.g. precise target volume definition not possible due to image artifacts created from a left ventricular assist device (LVAD))
  • Inability to consent or missing or withdrawn consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

University Clinic Mannheim

Mannheim, Baden-Wurttemberg, 68167, Germany

Location

Hospital of the Ludwig-Maximilians-University Munich

Munich, Bavaria, 80336, Germany

Location

Medizinische Hochschule Hannover

Hanover, Lower Saxony, 30625, Germany

Location

University Medical Center Schleswig-Holstein

Kiel, Schleswig-Holstein, 24105, Germany

Location

University Medical Center Schleswig-Holstein

Lübeck, Schleswig-Holstein, 23562, Germany

Location

University Medical Center Charite Berlin

Berlin, 10117, Germany

Location

Related Publications (9)

  • Blanck O, Buergy D, Vens M, Eidinger L, Zaman A, Krug D, Rudic B, Boda-Heggemann J, Giordano FA, Boldt LH, Mehrhof F, Budach V, Schweikard A, Olbrich D, Konig IR, Siebert FA, Vonthein R, Dunst J, Bonnemeier H. Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA). Clin Res Cardiol. 2020 Nov;109(11):1319-1332. doi: 10.1007/s00392-020-01650-9. Epub 2020 Apr 18.

    PMID: 32306083BACKGROUND
  • Boda-Heggemann J, Blanck O, Mehrhof F, Ernst F, Buergy D, Fleckenstein J, Tulumen E, Krug D, Siebert FA, Zaman A, Kluge AK, Parwani AS, Andratschke N, Mayinger MC, Ehrbar S, Saguner AM, Celik E, Baus WW, Stauber A, Vogel L, Schweikard A, Budach V, Dunst J, Boldt LH, Bonnemeier H, Rudic B. Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multicenter Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):745-756. doi: 10.1016/j.ijrobp.2021.01.028. Epub 2021 Jan 27.

    PMID: 33508373BACKGROUND
  • Krug D, Blanck O, Andratschke N, Guckenberger M, Jumeau R, Mehrhof F, Boda-Heggemann J, Seidensaal K, Dunst J, Pruvot E, Scholz E, Saguner AM, Rudic B, Boldt LH, Bonnemeier H. Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. Heart Rhythm. 2021 Dec;18(12):2137-2145. doi: 10.1016/j.hrthm.2021.08.004. Epub 2021 Aug 8.

    PMID: 34380072BACKGROUND
  • Kluge A, Ehrbar S, Grehn M, Fleckenstein J, Baus WW, Siebert FA, Schweikard A, Andratschke N, Mayinger MC, Boda-Heggemann J, Buergy D, Celik E, Krug D, Kovacs B, Saguner AM, Rudic B, Bergengruen P, Boldt LH, Stauber A, Zaman A, Bonnemeier H, Dunst J, Budach V, Blanck O, Mehrhof F. Treatment Planning for Cardiac Radioablation: Multicenter Multiplatform Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial. Int J Radiat Oncol Biol Phys. 2022 Jun 15;114(2):360-372. doi: 10.1016/j.ijrobp.2022.06.056.

    PMID: 35716847BACKGROUND
  • Mayinger M, Boda-Heggemann J, Mehrhof F, Krug D, Hohmann S, Xie J, Ehrbar S, Kovacs B, Merten R, Grehn M, Zaman A, Fleckenstein J, Kaestner L, Buergy D, Rudic B, Kluge A, Boldt LH, Dunst J, Bonnemeier H, Saguner AM, Andratschke N, Blanck O, Schweikard A. Quality assurance process within the RAdiosurgery for VENtricular TAchycardia (RAVENTA) trial for the fusion of electroanatomical mapping and radiotherapy planning imaging data in cardiac radioablation. Phys Imaging Radiat Oncol. 2022 Dec 26;25:100406. doi: 10.1016/j.phro.2022.12.003. eCollection 2023 Jan.

    PMID: 36655216BACKGROUND
  • Hohmann S, Xie J, Eckl M, Grehn M, Karfoul N, Janorschke C, Merten R, Rudic B, Buergy D, Lyan E, Krug D, Mehrhof F, Boldt LH, Corradini S, Fanslau H, Kaestner L, Zaman A, Giordano FA, Duncker D, Dunst J, Tilz RR, Schweikard A, Blanck O, Boda-Heggemann J. Semi-automated reproducible target transfer for cardiac radioablation - A multi-center cross-validation study within the RAVENTA trial. Radiother Oncol. 2024 Nov;200:110499. doi: 10.1016/j.radonc.2024.110499. Epub 2024 Sep 4.

    PMID: 39242029BACKGROUND
  • Krug D, Zaman A, Eidinger L, Grehn M, Boda-Heggemann J, Rudic B, Mehrhof F, Boldt LH, Hohmann S, Merten R, Buergy D, Fleckenstein J, Kluge A, Rogge A, Both M, Rades D, Tilz RR, Olbrich D, Konig IR, Siebert FA, Schweikard A, Vonthein R, Bonnemeier H, Dunst J, Blanck O. Radiosurgery for ventricular tachycardia (RAVENTA): interim analysis of a multicenter multiplatform feasibility trial. Strahlenther Onkol. 2023 Jul;199(7):621-630. doi: 10.1007/s00066-023-02091-9. Epub 2023 Jun 7.

  • Kaestner L, Boda-Heggemann J, Fanslau H, Xie J, Schweikard A, Giordano FA, Blanck O, Rudic B. Electroanatomical mapping after cardiac radioablation for treatment of incessant electrical storm: a case report from the RAVENTA trial. Strahlenther Onkol. 2023 Nov;199(11):1018-1024. doi: 10.1007/s00066-023-02136-z. Epub 2023 Sep 12.

  • Mehrhof F, Huttemeister J, Tanacli R, Bock M, Bogner M, Schoenrath F, Falk V, Zips D, Hindricks G, Gerds-Li JH, Hohendanner F. Cardiac radiotherapy transiently alters left ventricular electrical properties and induces cardiomyocyte-specific ventricular substrate changes in heart failure. Europace. 2023 Dec 28;26(1):euae005. doi: 10.1093/europace/euae005.

MeSH Terms

Conditions

Tachycardia, Ventricular

Condition Hierarchy (Ancestors)

TachycardiaArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Roland R Tilz, Prof.

    University Hospital Schleswig-Holstein

    PRINCIPAL INVESTIGATOR
  • Juergen Dunst, Prof.

    University Hospital Schleswig-Holstein

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. med. Juergen Dunst

Study Record Dates

First Submitted

March 5, 2019

First Posted

March 8, 2019

Study Start

December 2, 2019

Primary Completion

November 20, 2023

Study Completion

October 20, 2024

Last Updated

January 8, 2025

Record last verified: 2025-01

Locations